1. Home
  2. PHVS vs KW Comparison

PHVS vs KW Comparison

Compare PHVS & KW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • KW
  • Stock Information
  • Founded
  • PHVS 2015
  • KW 1977
  • Country
  • PHVS Switzerland
  • KW United States
  • Employees
  • PHVS N/A
  • KW N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • KW Real Estate
  • Sector
  • PHVS Health Care
  • KW Finance
  • Exchange
  • PHVS Nasdaq
  • KW Nasdaq
  • Market Cap
  • PHVS 1.3B
  • KW 1.1B
  • IPO Year
  • PHVS 2021
  • KW 1992
  • Fundamental
  • Price
  • PHVS $21.65
  • KW $8.80
  • Analyst Decision
  • PHVS Buy
  • KW
  • Analyst Count
  • PHVS 6
  • KW 0
  • Target Price
  • PHVS $36.67
  • KW N/A
  • AVG Volume (30 Days)
  • PHVS 118.6K
  • KW 827.8K
  • Earning Date
  • PHVS 08-12-2025
  • KW 08-06-2025
  • Dividend Yield
  • PHVS N/A
  • KW 5.45%
  • EPS Growth
  • PHVS N/A
  • KW N/A
  • EPS
  • PHVS N/A
  • KW N/A
  • Revenue
  • PHVS N/A
  • KW $531,500,000.00
  • Revenue This Year
  • PHVS N/A
  • KW $30.64
  • Revenue Next Year
  • PHVS N/A
  • KW $3.01
  • P/E Ratio
  • PHVS N/A
  • KW N/A
  • Revenue Growth
  • PHVS N/A
  • KW 6.96
  • 52 Week Low
  • PHVS $11.51
  • KW $5.98
  • 52 Week High
  • PHVS $26.33
  • KW $11.88
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 47.92
  • KW 71.37
  • Support Level
  • PHVS $21.56
  • KW $8.40
  • Resistance Level
  • PHVS $24.52
  • KW $8.54
  • Average True Range (ATR)
  • PHVS 1.32
  • KW 0.26
  • MACD
  • PHVS -0.07
  • KW 0.06
  • Stochastic Oscillator
  • PHVS 28.04
  • KW 97.14

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About KW Kennedy-Wilson Holdings Inc.

Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.

Share on Social Networks: